STOCK TITAN

Illumina Included on 2023 List of 100 Best Corporate Citizens List

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Illumina included on 2023 list of 100 Best Corporate Citizens
Positive
  • Illumina ranked #21 overall on the list
  • Illumina ranked #4 within the Pharmaceuticals, Biotechnology & Life Sciences industry
  • Illumina ranked #1 overall in the climate category
  • Illumina received the highest score in the 'climate change' pillar
  • In 2022, Illumina achieved 100% global electricity consumption from renewable sources
  • In 2022, Illumina achieved carbon neutrality in its own operations
  • In 2022, Illumina achieved a 61% climate impact reduction with the new product launch
  • Recognition for Illumina's strength in climate action, environmental stewardship, and social impact
Negative
  • None.

NORTHAMPTON, MA / ACCESSWIRE / October 19, 2023 / Illumina / Illumina has been included on the 2023 100 Best Corporate Citizens list by 3BL Media, recognizing outstanding environmental, social, and governance (ESG) performance among the 1,000 largest U.S. public companies. Illumina ranked #21 overall, #4 within the Pharmaceuticals, Biotechnology & Life Sciences industry, and #1 overall in the climate category.

Companies were researched by ISS and the ranking is based on 184 environmental, social, and governance (ESG) factors in seven pillars: climate change, employees, environment, governance, human rights, stakeholders and society, and ESG performance.

Illumina received the highest score in the ‘climate change' pillar out of all 1,000 companies analyzed. This pillar includes transparent reporting on climate change activities, including clear scope 1, 2, and 3 Greenhouse Gas (GHG) reduction targets, sub-targets, and performance.

In 2022, we made great progress against our sustainability targets, including:

  • 100% of global electricity consumption came from renewable sources, including renewable energy credits
  • Carbon neutral in our own operations (with the use of carbon offsets)
  • 61% climate impact reduction with the new product launch of NovaSeq X series compared to NovaSeq 6000
  • Our technology is being leveraged to help measure and mitigate the effects of climate change

Recognition also included strength in the categories of climate action, environmental stewardship, and social impact. Inclusion in this distinguished list reflects Illumina's commitment to positively impact the world and shape a more sustainable and equitable future for all.

View additional multimedia and more ESG storytelling from Illumina on 3blmedia.com.

Contact Info:
Spokesperson: Illumina
Website: https://www.3blmedia.com/profiles/illumina
Email: info@3blmedia.com

SOURCE: Illumina



View source version on accesswire.com:
https://www.accesswire.com/794612/illumina-included-on-2023-list-of-100-best-corporate-citizens-list

FAQ

What is the ranking of Illumina on the 2023 100 Best Corporate Citizens list?

Illumina ranked #21 overall on the list.

How did Illumina rank within the Pharmaceuticals, Biotechnology & Life Sciences industry?

Illumina ranked #4 within the industry.

What was Illumina's ranking in the climate category?

Illumina ranked #1 overall in the climate category.

What pillar did Illumina receive the highest score in?

Illumina received the highest score in the 'climate change' pillar.

What achievements did Illumina make in 2022?

In 2022, Illumina achieved 100% global electricity consumption from renewable sources, carbon neutrality in its own operations, and a 61% climate impact reduction with the new product launch.

What areas did Illumina receive recognition for?

Illumina received recognition for its strength in climate action, environmental stewardship, and social impact.

Illumina, Inc.

NASDAQ:ILMN

ILMN Rankings

ILMN Latest News

ILMN Stock Data

17.29B
158.41M
0.24%
94.5%
3.32%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About ILMN

at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.